These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 26598057)

  • 21. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical deployment of antibodies for treatment of melanoma.
    Curti BD; Urba WJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):18-27. PubMed ID: 25746916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
    Hassel JC; Heinzerling L; Aberle J; Bähr O; Eigentler TK; Grimm MO; Grünwald V; Leipe J; Reinmuth N; Tietze JK; Trojan J; Zimmer L; Gutzmer R
    Cancer Treat Rev; 2017 Jun; 57():36-49. PubMed ID: 28550712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
    Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
    J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors in the management of malignancies in transplant recipients.
    Regalla DKR; Williams GR; Paluri RK
    Postgrad Med J; 2018 Dec; 94(1118):704-708. PubMed ID: 30425139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
    Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint Blockade for the Treatment of Advanced Melanoma.
    Callahan MK; Flaherty CR; Postow MA
    Cancer Treat Res; 2016; 167():231-50. PubMed ID: 26601865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical Approaches to Immunotherapy in the Clinic.
    Agarwala SS
    Semin Oncol; 2015 Dec; 42 Suppl 3():S20-7. PubMed ID: 26598056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.
    Swanson MS; Sinha UK
    Oral Oncol; 2015 Jan; 51(1):12-5. PubMed ID: 25459157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
    Bakacs T; Mehrishi JN
    Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
    Hahn AW; Gill DM; Pal SK; Agarwal N
    Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ; Ott PA
    Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
    Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.